Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Jan 22

PMID 33477763

Citations 6

Authors

Ismael Valladolid-Acebes

Per-Olof Berggren

Lisa Juntti-Berggren

Affiliations

Soon will be listed here.

Abstract

It is well known that type-2 diabetes mellitus (T2D) is increasing worldwide, but also the autoimmune form, type-1 diabetes (T1D), is affecting more people. The latest estimation from the International Diabetes Federation (IDF) is that 1.1 million children and adolescents below 20 years of age have T1D. At present, we have no primary, secondary or tertiary prevention or treatment available, although many efforts testing different strategies have been made. This review is based on the findings that apolipoprotein CIII (apoCIII) is increased in T1D and that in vitro studies revealed that healthy β-cells exposed to apoCIII became apoptotic, together with the observation that humans with higher levels of the apolipoprotein, due to mutations in the gene, are more susceptible to developing T1D. We have summarized what is known about apoCIII in relation to inflammation and autoimmunity in in vitro and in vivo studies of T1D. The aim is to highlight the need for exploring this field as we still are only seeing the top of the iceberg.

Citing Articles

Multifaceted Role of Apolipoprotein C3 in Cardiovascular Disease Risk and Metabolic Disorder in Diabetes.

Pan B, Chen C, Chen F, Shen M Int J Mol Sci. 2024; 25(23.

PMID: 39684468 PMC: 11641554. DOI: 10.3390/ijms252312759.

The chylomicron saga: time to focus on postprandial metabolism.

Gugliucci A Front Endocrinol (Lausanne). 2024; 14:1322869.

PMID: 38303975 PMC: 10830840. DOI: 10.3389/fendo.2023.1322869.

Apolipoprotein-CIII -Glycosylation, a Link between and Plasma Lipids.

Naber A, Demus D, Slieker R, Nicolardi S, Beulens J, Elders P Int J Mol Sci. 2023; 24(19).

PMID: 37834292 PMC: 10573541. DOI: 10.3390/ijms241914844.

Plasma protein biomarkers predict the development of persistent autoantibodies and type 1 diabetes 6 months prior to the onset of autoimmunity.

Nakayasu E, Bramer L, Ansong C, Schepmoes A, Fillmore T, Gritsenko M Cell Rep Med. 2023; 4(7):101093.

PMID: 37390828 PMC: 10394168. DOI: 10.1016/j.xcrm.2023.101093.

Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia.

Boren J, Taskinen M, Bjornson E, Packard C Nat Rev Cardiol. 2022; 19(9):577-592.

PMID: 35318466 DOI: 10.1038/s41569-022-00676-y.

References

Kan H, Georgopoulos S, Zannis V . A hormone response element in the human apolipoprotein CIII (ApoCIII) enhancer is essential for intestinal expression of the ApoA-I and ApoCIII genes and contributes to the hepatic expression of the two linked genes in transgenic mice. J Biol Chem. 2000; 275(39):30423-31. DOI: 10.1074/jbc.M005641200. View

Blackett P, Sarale D, Fesmire J, Harmon J, Weech P, Alaupovic P . Plasma apolipoprotein C-III levels in children with type I diabetes. South Med J. 1988; 81(4):469-73. DOI: 10.1097/00007611-198804000-00015. View

Manzato E, Zambon A, Lapolla A, Zambon S, Braghetto L, Crepaldi G . Lipoprotein abnormalities in well-treated type II diabetic patients. Diabetes Care. 1993; 16(2):469-75. DOI: 10.2337/diacare.16.2.469. View

Chen M, Breslow J, Li W, Leff T . Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J Lipid Res. 1994; 35(11):1918-24. View

Towle H . Glucose as a regulator of eukaryotic gene transcription. Trends Endocrinol Metab. 2005; 16(10):489-94. DOI: 10.1016/j.tem.2005.10.003. View

Ginsberg H, Le N, Goldberg I, Gibson J, Rubinstein A, Norum R . Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 1986; 78(5):1287-95. PMC: 423815. DOI: 10.1172/JCI112713. View

Gervaise N, Garrigue M, Lasfargues G, Lecomte P . Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia. 2000; 43(6):703-8. DOI: 10.1007/s001250051366. View

Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas F, Sacks F . Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation. 2006; 113(5):691-700. DOI: 10.1161/CIRCULATIONAHA.105.591743. View

Lacorte J, Beigneux A, Parant M, Chambaz J . Repression of apoC-III gene expression by TNFalpha involves C/EBPdelta/NF-IL6beta via an IL-1 independent pathway. FEBS Lett. 1997; 415(2):217-20. DOI: 10.1016/s0014-5793(97)01127-7. View

10.

Steck A, Vehik K, Bonifacio E, Lernmark A, Ziegler A, Hagopian W . Predictors of Progression From the Appearance of Islet Autoantibodies to Early Childhood Diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY). Diabetes Care. 2015; 38(5):808-13. PMC: 4407751. DOI: 10.2337/dc14-2426. View

11.

Lambert D, Smith L, Pownall H, Sparrow J, Nicolas J, Gotto Jr A . Hydrolysis of phospholipids by purified milk lipoprotein lipase. Effect of apoprotein CII, CIII, A and E, and synthetic fragments. Clin Chim Acta. 1999; 291(1):19-33. DOI: 10.1016/s0009-8981(99)00193-x. View

12.

Joven J, Vilella E, Costa B, Turner P, Richart C, Masana L . Concentrations of lipids and apolipoproteins in patients with clinically well-controlled insulin-dependent and non-insulin-dependent diabetes. Clin Chem. 1989; 35(5):813-6. View

13.

Yamashita H, Takenoshita M, Sakurai M, Bruick R, Henzel W, Shillinglaw W . A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc Natl Acad Sci U S A. 2001; 98(16):9116-21. PMC: 55382. DOI: 10.1073/pnas.161284298. View

14.

Sacks F, Alaupovic P, Moye L, Cole T, Sussex B, Stampfer M . VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000; 102(16):1886-92. DOI: 10.1161/01.cir.102.16.1886. View

15.

Barrett J, Clayton D, Concannon P, Akolkar B, Cooper J, Erlich H . Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet. 2009; 41(6):703-7. PMC: 2889014. DOI: 10.1038/ng.381. View

16.

Xu G, Chen J, Jing G, Shalev A . Preventing β-cell loss and diabetes with calcium channel blockers. Diabetes. 2012; 61(4):848-56. PMC: 3314354. DOI: 10.2337/db11-0955. View

17.

Holmberg R, Refai E, Hoog A, Crooke R, Graham M, Olivecrona G . Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proc Natl Acad Sci U S A. 2011; 108(26):10685-9. PMC: 3127896. DOI: 10.1073/pnas.1019553108. View

18.

Frostegard J . SLE, atherosclerosis and cardiovascular disease. J Intern Med. 2005; 257(6):485-95. DOI: 10.1111/j.1365-2796.2005.01502.x. View

19.

Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J . Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis. 1996; 122(1):105-15. DOI: 10.1016/0021-9150(95)05791-9. View

20.

Zvintzou E, Lhomme M, Chasapi S, Filou S, Theodoropoulos V, Xapapadaki E . Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity. J Lipid Res. 2017; 58(9):1869-1883. PMC: 5580900. DOI: 10.1194/jlr.M077925. View